Literature DB >> 28848890

Evaluation of Individuals at Risk for COPD: Beyond the Scope of the Global Initiative for Chronic Obstructive Lung Disease.

Julio D Antuni1, Peter J Barnes2.   

Abstract

The Global initiative for chronic Obstructive Lung Disease (GOLD) Strategy is a valuable tool for clinicians in the diagnosis and management of patients with established chronic obstructive pulmonary disease (COPD). However, there are no recommendations for the evaluation of individuals, exposed to risk factors, who are most likely to develop COPD. Consequently, it is necessary to consider all of the factors that may play a role in the pathogenesis of COPD: genetic factors, gender, socioeconomic status, disadvantageous factors in childhood, lung diseases and exposure to risk factors such as smoking, biomass fuel smoke, occupational hazards and air pollution. Along with the clinical assessment, periodic spirometry should be performed to evaluate lung function and make possible early detection of individuals who will develop the disease through the rate of forced expiratory volume in 1 second (FEV1) decline. The first spirometry, periodicity, and clinically significant decline in FEV1 will encompass the cornerstones of clinical follow up. This approach allows the implementation of important interventions in order to help individuals to cease contact with risk factors and prevent progressive respiratory impairment with the consequent deterioration of quality of life and increased morbidity and mortality.

Entities:  

Keywords:  FEV1 decline; GOLD; Global initiative for chronic Obstructive Lung Dis; chronic obstructive pulmonary disease; copd; risk factors

Year:  2016        PMID: 28848890      PMCID: PMC5556761          DOI: 10.15326/jcopdf.3.3.2016.0129

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  123 in total

1.  Increased mortality in COPD among construction workers exposed to inorganic dust.

Authors:  I A Bergdahl; K Torén; K Eriksson; U Hedlund; T Nilsson; R Flodin; B Järvholm
Journal:  Eur Respir J       Date:  2004-03       Impact factor: 16.671

2.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

Review 3.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

4.  Protective role for club cell secretory protein-16 (CC16) in the development of COPD.

Authors:  Maria E Laucho-Contreras; Francesca Polverino; Kushagra Gupta; Katherine L Taylor; Emer Kelly; Victor Pinto-Plata; Miguel Divo; Naveed Ashfaq; Hans Petersen; Barry Stripp; Aprile L Pilon; Yohannes Tesfaigzi; Bartolome R Celli; Caroline A Owen
Journal:  Eur Respir J       Date:  2015-02-19       Impact factor: 16.671

5.  Effects of smoking and changes in smoking habits on the decline of FEV1.

Authors:  P Lange; S Groth; G J Nyboe; J Mortensen; M Appleyard; G Jensen; P Schnohr
Journal:  Eur Respir J       Date:  1989-10       Impact factor: 16.671

6.  Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group.

Authors:  D P Tashkin; M D Altose; J E Connett; R E Kanner; W W Lee; R A Wise
Journal:  Am J Respir Crit Care Med       Date:  1996-06       Impact factor: 21.405

7.  CT-quantified emphysema in male heavy smokers: association with lung function decline.

Authors:  Firdaus A A Mohamed Hoesein; Bartjan de Hoop; Pieter Zanen; Hester Gietema; Cas L J J Kruitwagen; Bram van Ginneken; Ivana Isgum; Christian Mol; Rob J van Klaveren; Akkelies E Dijkstra; Harry J M Groen; H Marike Boezen; Dirkje S Postma; Mathias Prokop; Jan-Willem J Lammers
Journal:  Thorax       Date:  2011-04-07       Impact factor: 9.139

8.  Developing COPD: a 25 year follow up study of the general population.

Authors:  A Løkke; P Lange; H Scharling; P Fabricius; J Vestbo
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

9.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 10.  The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation.

Authors:  B W M Willemse; D S Postma; W Timens; N H T ten Hacken
Journal:  Eur Respir J       Date:  2004-03       Impact factor: 16.671

View more
  4 in total

1.  At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease.

Authors:  Fernando J Martinez; MeiLan K Han; James P Allinson; R Graham Barr; Richard C Boucher; Peter M A Calverley; Bartolome R Celli; Stephanie A Christenson; Ronald G Crystal; Malin Fagerås; Christine M Freeman; Lars Groenke; Eric A Hoffman; Mehmet Kesimer; Kostantinos Kostikas; Robert Paine; Shahin Rafii; Stephen I Rennard; Leopoldo N Segal; Renat Shaykhiev; Christopher Stevenson; Ruth Tal-Singer; Jørgen Vestbo; Prescott G Woodruff; Jeffrey L Curtis; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2018-06-15       Impact factor: 21.405

2.  Higher Blood Vascular Cell Adhesion Molecule-1 is Related to the Increased Risk of Cardiovascular Events in Chronic Obstructive Pulmonary Disease.

Authors:  Jinlin Li; Qi Wang; Qingping Zhang; Zhengyan Wang; Xin Wan; Chenfang Miao; Xi Zeng
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-09-28

3.  Qualitative systematic review of barriers and facilitators to self-management of chronic obstructive pulmonary disease: views of patients and healthcare professionals.

Authors:  Siân Russell; Oladapo J Ogunbayo; James J Newham; Karen Heslop-Marshall; Paul Netts; Barbara Hanratty; Fiona Beyer; Eileen Kaner
Journal:  NPJ Prim Care Respir Med       Date:  2018-01-17       Impact factor: 2.871

4.  Elevated serum matrix metalloprotease (MMP-2) as a candidate biomarker for stable COPD.

Authors:  Durga Mahor; Vandana Kumari; Kapil Vashisht; Ruma Galgalekar; Ravindra M Samarth; Pradyumna K Mishra; Nalok Banerjee; Rajnikant Dixit; Rohit Saluja; Sajal De; Kailash C Pandey
Journal:  BMC Pulm Med       Date:  2020-11-16       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.